MR-guided microwave ablation of liver tumors: outcomes in local tumor control and determinants of treatment success - Scorecard - MDSpire

MR-guided microwave ablation of liver tumors: outcomes in local tumor control and determinants of treatment success

  • By

  • Vanessa F. Schmidt

  • Philipp Linden

  • Olaf Dietrich

  • Sinan Deniz

  • Daniel Puhr-Westerheide

  • Osman Öcal

  • Moritz L. Schnitzer

  • Florian Obereisenbuchner

  • Matthias Kassube

  • Mingming Wu

  • Luigi Nardone

  • Lars Grenacher

  • Florian Maier

  • Ricarda Seidensticker

  • Moritz Wildgruber

  • Jens Ricke

  • Matthias P. Fabritius

  • Max Seidensticker

  • July 4, 2026

  • 0 min

Share

Clinical Scorecard: Microwave Ablation of Hepatic Tumors Under MR Guidance: Efficacy in Local Control and Factors Influencing Treatment Success

At a Glance

CategoryDetail
ConditionHepatic Tumors
Key MechanismsMinimally invasive thermal ablation using microwave technology for local tumor control.
Target PopulationPatients with primary and secondary liver malignancies.
Care SettingInterventional radiology with MR guidance.

Key Highlights

  • Microwave ablation (MWA) offers higher intratumoral temperatures and larger ablation volumes compared to radiofrequency ablation.
  • MR imaging provides superior soft tissue contrast for accurate lesion localization and monitoring.
  • Technical success rate of 95.8% was achieved with MR-guided MWA.
  • Factors influencing treatment success include lesion size, type, and proximity to vascular structures.
  • Complications were minimal, with only 2.5% experiencing postprocedural issues.

Guideline-Based Recommendations

Diagnosis

  • Histopathological confirmation of liver malignancies is required prior to MWA.

Management

  • Multidisciplinary tumor board involvement in treatment decision-making for MWA.

Monitoring & Follow-up

  • MR thermometry should be utilized for continuous temperature monitoring during ablation.

Risks

  • Potential complications include bleeding and pleural effusion, though these are rare.

Patient & Prescribing Data

40 patients with a median age of 62.5 years, predominantly male.

Prior treatments were common, with 65% having received systemic therapy or other local ablative therapies.

Clinical Best Practices

  • Utilize MR imaging for precise targeting and monitoring during MWA.
  • Ensure adequate safety margins from adjacent vascular structures during ablation.
  • Conduct follow-up imaging to assess local tumor control post-ablation.

Related Resources & Content

Original Source(s)

Related Content